메뉴 건너뛰기




Volumn 79, Issue 2, 2011, Pages 144-153

A novel perspective for an orphan problem: Old and new drugs for the medical management of malignant ascites

Author keywords

Antiangiogenetic agents; Biological therapies; Bispecific antibodies; Diuretics; Intraperitoneal chemotherapy; Malignant ascites; Paracentesis

Indexed keywords

BATIMASTAT; BLEOMYCIN; BUMETANIDE; CARBOPLATIN; CATUMAXOMAB; CHLORMETHINE; CISPLATIN; CYTARABINE; DIURETIC AGENT; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; FUROSEMIDE; MELPHALAN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; PLACEBO; SPIRONOLACTONE; SUNITINIB; THIOTEPA; TOPOTECAN; TRIAMCINOLONE HEXACETONIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

EID: 79960171737     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.07.016     Document Type: Review
Times cited : (37)

References (74)
  • 1
    • 34447298354 scopus 로고    scopus 로고
    • Pattern and prognostic factors in patients with malignant ascites: a retrospective study
    • Ayantunde A.A., Parsons S.L. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007, 18:945-949.
    • (2007) Ann Oncol , vol.18 , pp. 945-949
    • Ayantunde, A.A.1    Parsons, S.L.2
  • 3
    • 0033953879 scopus 로고    scopus 로고
    • Paracentesis-an effective method of symptom control in the palliative care setting?
    • McNamara P. Paracentesis-an effective method of symptom control in the palliative care setting?. Palliat Med 2000, 14:62-64.
    • (2000) Palliat Med , vol.14 , pp. 62-64
    • McNamara, P.1
  • 4
    • 0032144098 scopus 로고    scopus 로고
    • A survey of practice in management of malignant ascites
    • Lee C.W., Bociek G., Faught W. A survey of practice in management of malignant ascites. J Pain Symptom Manage 1998, 16:96-101.
    • (1998) J Pain Symptom Manage , vol.16 , pp. 96-101
    • Lee, C.W.1    Bociek, G.2    Faught, W.3
  • 6
    • 0020602804 scopus 로고
    • Peritoneovenous shunts in the management of malignant ascites
    • Souter R.G., Tarin D., Kettlewell M.G. Peritoneovenous shunts in the management of malignant ascites. Br J Surg 1983, 70:478-481.
    • (1983) Br J Surg , vol.70 , pp. 478-481
    • Souter, R.G.1    Tarin, D.2    Kettlewell, M.G.3
  • 7
    • 0020061153 scopus 로고
    • Peritoneovenous shunt for palliation of malignant ascites
    • Qazi R., Savlov E.D. Peritoneovenous shunt for palliation of malignant ascites. Cancer 1982, 49:600-602.
    • (1982) Cancer , vol.49 , pp. 600-602
    • Qazi, R.1    Savlov, E.D.2
  • 8
    • 33644765785 scopus 로고    scopus 로고
    • Malignant ascites: systematic review and guideline for treatment
    • Becker G., Galandi D., Blum H.E. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 2006, 42:589-597.
    • (2006) Eur J Cancer , vol.42 , pp. 589-597
    • Becker, G.1    Galandi, D.2    Blum, H.E.3
  • 9
    • 0029901208 scopus 로고    scopus 로고
    • Malignant ascites: a 2-year review from a teaching hospital
    • Parsons S.L., Lang M.W., Steele R.J. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol 1996, 22:237-239.
    • (1996) Eur J Surg Oncol , vol.22 , pp. 237-239
    • Parsons, S.L.1    Lang, M.W.2    Steele, R.J.3
  • 10
    • 0000655999 scopus 로고
    • Use of nitrogen mustard in treatment of serous effusions of neoplastic origin
    • Weisberger A.S., Levine B., Storaasli J.P. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc 1955, 159:1704-1707.
    • (1955) J Am Med Assoc , vol.159 , pp. 1704-1707
    • Weisberger, A.S.1    Levine, B.2    Storaasli, J.P.3
  • 11
    • 0019972828 scopus 로고
    • On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed?
    • Appelqvist P., Silvo J., Salmela L., Kostiainen S. On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed?. J Surg Oncol 1982, 20:238-242.
    • (1982) J Surg Oncol , vol.20 , pp. 238-242
    • Appelqvist, P.1    Silvo, J.2    Salmela, L.3    Kostiainen, S.4
  • 12
    • 0022616909 scopus 로고
    • An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavity bleomycin
    • Ostrowski M.J. An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavity bleomycin. Cancer 1986, 57:721-727.
    • (1986) Cancer , vol.57 , pp. 721-727
    • Ostrowski, M.J.1
  • 13
    • 0028225234 scopus 로고
    • Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin
    • Maiche A.G. Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin. Anticancer Drugs 1994, 5:305-308.
    • (1994) Anticancer Drugs , vol.5 , pp. 305-308
    • Maiche, A.G.1
  • 14
    • 0043245891 scopus 로고    scopus 로고
    • Intraperitoneal chemotherapy with mitoxantrone in malignant ascites
    • xvi-xvii
    • Link K.H., Roitman M., Holtappels M., et al. Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. Surg Oncol Clin N Am 2003, 12:865-872. xvi-xvii.
    • (2003) Surg Oncol Clin N Am , vol.12 , pp. 865-872
    • Link, K.H.1    Roitman, M.2    Holtappels, M.3
  • 15
    • 38749089075 scopus 로고    scopus 로고
    • A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites
    • Oh S.Y., Kwon H.C., Lee S., et al. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol 2007, 37:930-935.
    • (2007) Jpn J Clin Oncol , vol.37 , pp. 930-935
    • Oh, S.Y.1    Kwon, H.C.2    Lee, S.3
  • 16
    • 0025689079 scopus 로고
    • Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer
    • Schilsky R.L., Choi K.E., Grayhack J., Grimmer D., Guarnieri C., Fullem L. Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol 1990, 8:2054-2061.
    • (1990) J Clin Oncol , vol.8 , pp. 2054-2061
    • Schilsky, R.L.1    Choi, K.E.2    Grayhack, J.3    Grimmer, D.4    Guarnieri, C.5    Fullem, L.6
  • 17
    • 0026724629 scopus 로고
    • Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma
    • Markman M., Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992, 118:547-550.
    • (1992) J Cancer Res Clin Oncol , vol.118 , pp. 547-550
    • Markman, M.1    Kelsen, D.2
  • 19
    • 0027058837 scopus 로고
    • Treatment of malignant peritoneal effusion in digestive and ovarian cancer
    • Gilly F.N., Carry P.Y., Brachet A., et al. Treatment of malignant peritoneal effusion in digestive and ovarian cancer. Med Oncol Tumor Pharmacother 1992, 9:177-181.
    • (1992) Med Oncol Tumor Pharmacother , vol.9 , pp. 177-181
    • Gilly, F.N.1    Carry, P.Y.2    Brachet, A.3
  • 20
    • 0031263279 scopus 로고    scopus 로고
    • Intraperitoneal chemo-hyperthermia with mitomycin C in cancer of the stomach with peritoneal carcinosis
    • François Y., Grandclément E., Sayag-Beaujard A.C., et al. Intraperitoneal chemo-hyperthermia with mitomycin C in cancer of the stomach with peritoneal carcinosis. J Chir (Paris) 1997, 134:237-242.
    • (1997) J Chir (Paris) , vol.134 , pp. 237-242
    • François, Y.1    Grandclément, E.2    Sayag-Beaujard, A.C.3
  • 21
    • 33745992965 scopus 로고    scopus 로고
    • Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites
    • Garofalo A., Valle M., Garcia J., Sugarbaker P.H. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol 2006, 32:682-685.
    • (2006) Eur J Surg Oncol , vol.32 , pp. 682-685
    • Garofalo, A.1    Valle, M.2    Garcia, J.3    Sugarbaker, P.H.4
  • 22
    • 0027369739 scopus 로고
    • Continuous hyperthermic peritoneal perfusion (CHPP) for prevention or treatment of peritoneal dissemination
    • Kusano H., Miyashita K., Matsuo T., et al. Continuous hyperthermic peritoneal perfusion (CHPP) for prevention or treatment of peritoneal dissemination. Gan To Kagaku Ryoho 1993, 20:1622-1625.
    • (1993) Gan To Kagaku Ryoho , vol.20 , pp. 1622-1625
    • Kusano, H.1    Miyashita, K.2    Matsuo, T.3
  • 24
    • 0031034105 scopus 로고    scopus 로고
    • Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy
    • Loggie B.W., Perini M., Fleming R.A., Russell G.B., Geisinger K. Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. Am Surg 1997, 63:137-143.
    • (1997) Am Surg , vol.63 , pp. 137-143
    • Loggie, B.W.1    Perini, M.2    Fleming, R.A.3    Russell, G.B.4    Geisinger, K.5
  • 25
    • 0034098315 scopus 로고    scopus 로고
    • Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin
    • Loggie B.W., Fleming R.A., McQuellon R.P., Russell G.B., Geisinger K.R. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000, 66:561-568.
    • (2000) Am Surg , vol.66 , pp. 561-568
    • Loggie, B.W.1    Fleming, R.A.2    McQuellon, R.P.3    Russell, G.B.4    Geisinger, K.R.5
  • 26
    • 50849099547 scopus 로고    scopus 로고
    • Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination
    • Esquivel J., Elias D., Baratti D., Kusamura S., Deraco M. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol 2008, 98:263-267.
    • (2008) J Surg Oncol , vol.98 , pp. 263-267
    • Esquivel, J.1    Elias, D.2    Baratti, D.3    Kusamura, S.4    Deraco, M.5
  • 27
    • 50849103061 scopus 로고    scopus 로고
    • Locoregional treatment of peritoneal carcinomatosis from gastric cancer
    • Bozzetti F., Yu W., Baratti D., Kusamura S., Deraco M. Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol 2008, 98:273-276.
    • (2008) J Surg Oncol , vol.98 , pp. 273-276
    • Bozzetti, F.1    Yu, W.2    Baratti, D.3    Kusamura, S.4    Deraco, M.5
  • 28
    • 50849119765 scopus 로고    scopus 로고
    • Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer
    • Helm C.W., Bristow R.E., Kusamura S., Baratti D., Deraco M. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol 2008, 98:283-290.
    • (2008) J Surg Oncol , vol.98 , pp. 283-290
    • Helm, C.W.1    Bristow, R.E.2    Kusamura, S.3    Baratti, D.4    Deraco, M.5
  • 29
    • 0024390361 scopus 로고
    • Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer
    • Bezwoda W.R., Seymour L., Dansey R. Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer. Cancer 1989, 64:1029-1033.
    • (1989) Cancer , vol.64 , pp. 1029-1033
    • Bezwoda, W.R.1    Seymour, L.2    Dansey, R.3
  • 30
    • 0035742687 scopus 로고    scopus 로고
    • Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions A prospective pilot study
    • Sartori S., Nielsen I., Tassinari D., Trevisani L., Abbasciano V., Malacarne P. Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions A prospective pilot study. Oncology 2001, 61:192-196.
    • (2001) Oncology , vol.61 , pp. 192-196
    • Sartori, S.1    Nielsen, I.2    Tassinari, D.3    Trevisani, L.4    Abbasciano, V.5    Malacarne, P.6
  • 31
    • 0027534622 scopus 로고
    • Intraperitoneal interferon in the management of malignant ascites
    • Stuart G.C., Nation J.G., Snider D.D., Thunberg P. Intraperitoneal interferon in the management of malignant ascites. Cancer 1993, 71:2027-2030.
    • (1993) Cancer , vol.71 , pp. 2027-2030
    • Stuart, G.C.1    Nation, J.G.2    Snider, D.D.3    Thunberg, P.4
  • 32
    • 0028177909 scopus 로고
    • Intracavitary treatment of malignant pleural and peritoneal effusions in cancer patients
    • B
    • Gebbia N., Mannino R., Di Dino A., et al. Intracavitary treatment of malignant pleural and peritoneal effusions in cancer patients. Anticancer Res 1994, 14(2B):739-745.
    • (1994) Anticancer Res , vol.14 , Issue.2 , pp. 739-745
    • Gebbia, N.1    Mannino, R.2    Di Dino, A.3
  • 33
    • 0031030209 scopus 로고    scopus 로고
    • A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma
    • Hirte H.W., Miller D., Tonkin K., et al. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma. Gynecol Oncol 1997, 64:80-87.
    • (1997) Gynecol Oncol , vol.64 , pp. 80-87
    • Hirte, H.W.1    Miller, D.2    Tonkin, K.3
  • 34
    • 0020472233 scopus 로고
    • Human leukocyte interferon therapy for advanced ovarian carcinoma
    • Einhorn N., Cantell K., Einhorn S., Strander H. Human leukocyte interferon therapy for advanced ovarian carcinoma. Am J Clin Oncol 1982, 5:167-172.
    • (1982) Am J Clin Oncol , vol.5 , pp. 167-172
    • Einhorn, N.1    Cantell, K.2    Einhorn, S.3    Strander, H.4
  • 35
    • 0025981202 scopus 로고
    • Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites
    • Rath U., Kaufmann M., Schmid H., et al. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. Eur J Cancer 1991, 27:121-125.
    • (1991) Eur J Cancer , vol.27 , pp. 121-125
    • Rath, U.1    Kaufmann, M.2    Schmid, H.3
  • 36
    • 0020507993 scopus 로고
    • Intracavitary Corynebacterium parvum for treatment of malignant effusions
    • Currie J.L., Gall S., Weed J.C., Creasman W.T. Intracavitary Corynebacterium parvum for treatment of malignant effusions. Gynecol Oncol 1983, 16:6-14.
    • (1983) Gynecol Oncol , vol.16 , pp. 6-14
    • Currie, J.L.1    Gall, S.2    Weed, J.C.3    Creasman, W.T.4
  • 37
    • 0020627970 scopus 로고
    • New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell mediated tumor cell destruction
    • Katano M., Torisu M. New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell mediated tumor cell destruction. Surgery 1983, 93:365-373.
    • (1983) Surgery , vol.93 , pp. 365-373
    • Katano, M.1    Torisu, M.2
  • 38
    • 0020541025 scopus 로고
    • New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival
    • Torisu M., Katano M., Kimura Y., Itoh H., Takesue M. New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 1983, 93:357-364.
    • (1983) Surgery , vol.93 , pp. 357-364
    • Torisu, M.1    Katano, M.2    Kimura, Y.3    Itoh, H.4    Takesue, M.5
  • 39
    • 0347382821 scopus 로고    scopus 로고
    • Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+Th1 killer lymphocytes
    • Yamaguchi Y., Miyahara E., Ohshita A., et al. Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+Th1 killer lymphocytes. Br J Cancer 2003, 89:1876-1884.
    • (2003) Br J Cancer , vol.89 , pp. 1876-1884
    • Yamaguchi, Y.1    Miyahara, E.2    Ohshita, A.3
  • 40
    • 0031797119 scopus 로고    scopus 로고
    • The past, the present and future of the OK-432 therapy for patients with malignant effusions
    • Katano M., Morisaki T. The past, the present and future of the OK-432 therapy for patients with malignant effusions. Anticancer Res 1998, 18:3917-3925.
    • (1998) Anticancer Res , vol.18 , pp. 3917-3925
    • Katano, M.1    Morisaki, T.2
  • 41
    • 84856104578 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/ct2/show/NCT00822809Zterm=ascites&rank=9.
  • 42
    • 0034069424 scopus 로고    scopus 로고
    • A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites
    • Mackey J.R., Wood L., Nabholtz J., et al. A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites. J Pain Symptom Manage 2000, 19:193-199.
    • (2000) J Pain Symptom Manage , vol.19 , pp. 193-199
    • Mackey, J.R.1    Wood, L.2    Nabholtz, J.3
  • 43
    • 34447132202 scopus 로고    scopus 로고
    • Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM×anti-CD3 antibody: a phase I/II study
    • Burges A., Wimberger P., Kumper C., et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM×anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007, 13:3899-3905.
    • (2007) Clin Cancer Res , vol.13 , pp. 3899-3905
    • Burges, A.1    Wimberger, P.2    Kumper, C.3
  • 44
    • 42449141210 scopus 로고    scopus 로고
    • Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: a matched-pair analysis
    • S, [abstr 2544]
    • Stroehlein M., Gruetzner K., Tarbichi A., et al. Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: a matched-pair analysis. J Clin Oncol 2006, 24(18S). [abstr 2544].
    • (2006) J Clin Oncol , vol.24 , Issue.18
    • Stroehlein, M.1    Gruetzner, K.2    Tarbichi, A.3
  • 45
    • 67549087235 scopus 로고    scopus 로고
    • Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM×anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients
    • [43rd June 02 Abs 5556]
    • Belau A., Pfisterer J., Wimberger P., et al. Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM×anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients. Am Soc Clin Oncol 2007, [43rd June 02 Abs 5556].
    • (2007) Am Soc Clin Oncol
    • Belau, A.1    Pfisterer, J.2    Wimberger, P.3
  • 46
    • 52949107017 scopus 로고    scopus 로고
    • Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: results of a phase II/III study
    • [43rd June 03 Abstr 5520]
    • Parsons S.L., Kutarska E., Koralewski P., et al. Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: results of a phase II/III study. Am Soc Clin Oncol 2007, [43rd June 03 Abstr 5520].
    • (2007) Am Soc Clin Oncol
    • Parsons, S.L.1    Kutarska, E.2    Koralewski, P.3
  • 47
    • 52949109375 scopus 로고    scopus 로고
    • Treatment of epithelial cancer patients with malignant ascites using catumaxomab: results of the non-ovarian stratum of a phase II/III study
    • [abstr 102]
    • Parsons S.L., Muarwa P.X., Kolesnik O.O., et al. Treatment of epithelial cancer patients with malignant ascites using catumaxomab: results of the non-ovarian stratum of a phase II/III study. Proc Gastrointest Cancer Symp 2008, [abstr 102].
    • (2008) Proc Gastrointest Cancer Symp
    • Parsons, S.L.1    Muarwa, P.X.2    Kolesnik, O.O.3
  • 48
    • 77953373836 scopus 로고    scopus 로고
    • Pharmacokinetics and in vivo stability of intraperitoneally administered therapeutic antibody catumaxomab
    • [May 20 suppl; abstr 14006]
    • Ruf P., Jäger M., Volovat C., et al. Pharmacokinetics and in vivo stability of intraperitoneally administered therapeutic antibody catumaxomab. J Clin Oncol 2008, 26. [May 20 suppl; abstr 14006].
    • (2008) J Clin Oncol , vol.26
    • Ruf, P.1    Jäger, M.2    Volovat, C.3
  • 49
    • 63649133396 scopus 로고    scopus 로고
    • Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab)(anti-EpCAM×anti-CD3): results of a phase I/II study
    • Sebastian M., Kiewe P., Schuette W., et al. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab)(anti-EpCAM×anti-CD3): results of a phase I/II study. J Immunother 2009, 32:195-202.
    • (2009) J Immunother , vol.32 , pp. 195-202
    • Sebastian, M.1    Kiewe, P.2    Schuette, W.3
  • 50
    • 34447642376 scopus 로고    scopus 로고
    • Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM×anti-CD3): a phase I study
    • Sebastian M., Passlick B., Friccius-Quecke H., et al. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM×anti-CD3): a phase I study. Cancer Immunol Immunother 2007, 56:1637-1644.
    • (2007) Cancer Immunol Immunother , vol.56 , pp. 1637-1644
    • Sebastian, M.1    Passlick, B.2    Friccius-Quecke, H.3
  • 51
    • 84856103822 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/ct2/show/NCT00822809Zterm=ascites&rank=9.
  • 52
    • 0034072645 scopus 로고    scopus 로고
    • Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo
    • Yukita A., Asano M., Okamoto T., Mizutani S., Suzuki H. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo. Anticancer Res 2000, 20:155-160.
    • (2000) Anticancer Res , vol.20 , pp. 155-160
    • Yukita, A.1    Asano, M.2    Okamoto, T.3    Mizutani, S.4    Suzuki, H.5
  • 53
    • 56449083159 scopus 로고    scopus 로고
    • The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report
    • Kesterson J.P., Mhawech-Fauceglia P., Lele S. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol 2008, 111:527-529.
    • (2008) Gynecol Oncol , vol.111 , pp. 527-529
    • Kesterson, J.P.1    Mhawech-Fauceglia, P.2    Lele, S.3
  • 55
    • 33748475636 scopus 로고    scopus 로고
    • The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma
    • Numnum T.M., Rocconi R.P., Whitworth J., Barnes M.N. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 2006, 102:425-428.
    • (2006) Gynecol Oncol , vol.102 , pp. 425-428
    • Numnum, T.M.1    Rocconi, R.P.2    Whitworth, J.3    Barnes, M.N.4
  • 57
    • 0031848158 scopus 로고    scopus 로고
    • Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites
    • Beattie G.J., Smyth J.F. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 1998, 4:1899-1902.
    • (1998) Clin Cancer Res , vol.4 , pp. 1899-1902
    • Beattie, G.J.1    Smyth, J.F.2
  • 58
    • 0031461180 scopus 로고    scopus 로고
    • Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites
    • Parsons S.L., Watson S.A., Steele R.J. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 1997, 23:526-531.
    • (1997) Eur J Surg Oncol , vol.23 , pp. 526-531
    • Parsons, S.L.1    Watson, S.A.2    Steele, R.J.3
  • 59
    • 0032830056 scopus 로고    scopus 로고
    • Octreotide as an agent for the relief of malignant ascites in palliative care patients
    • Cairns W., Malone R. Octreotide as an agent for the relief of malignant ascites in palliative care patients. Palliat Med 1999, 13:429-430.
    • (1999) Palliat Med , vol.13 , pp. 429-430
    • Cairns, W.1    Malone, R.2
  • 60
    • 14644386870 scopus 로고    scopus 로고
    • The successful treatment of chylous effusions in malignant disease with octreotide
    • Mincher L., Evans J., Jenner M.W., Varney V.A. The successful treatment of chylous effusions in malignant disease with octreotide. Clin Oncol (R Coll Radiol) 2005, 17:118-121.
    • (2005) Clin Oncol (R Coll Radiol) , vol.17 , pp. 118-121
    • Mincher, L.1    Evans, J.2    Jenner, M.W.3    Varney, V.A.4
  • 61
    • 84856081845 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/ct2/show/NCT00182754Zintr=%22Octreotide%22&rank=40.
  • 62
    • 2942616642 scopus 로고
    • Treatment of pleural and peritoneal effusion with intracavitary colloidal radiogold (Au 198)
    • Dybicki J., Balchum O.J., Meneely G.R. Treatment of pleural and peritoneal effusion with intracavitary colloidal radiogold (Au 198). Arch Intern Med 1959, 104:802-815.
    • (1959) Arch Intern Med , vol.104 , pp. 802-815
    • Dybicki, J.1    Balchum, O.J.2    Meneely, G.R.3
  • 63
    • 2942577573 scopus 로고    scopus 로고
    • Malignant ascites: past, present, and future
    • Adam R.A., Adam Y.G. Malignant ascites: past, present, and future. J Am Coll Surg 2004, 198:999-1011.
    • (2004) J Am Coll Surg , vol.198 , pp. 999-1011
    • Adam, R.A.1    Adam, Y.G.2
  • 64
    • 0013942152 scopus 로고
    • Intracavitary administration of radioactive isotopes in the control of effusions due to cancer. Results in 267 patients
    • Ariel I.M., Oropeza R., Pack G.T. Intracavitary administration of radioactive isotopes in the control of effusions due to cancer. Results in 267 patients. Cancer 1966, 19:1096-1102.
    • (1966) Cancer , vol.19 , pp. 1096-1102
    • Ariel, I.M.1    Oropeza, R.2    Pack, G.T.3
  • 65
    • 2942565837 scopus 로고
    • Radioactive colloidal chromic phosphate to control pleural effusion and ascites
    • Jacobs M.L. Radioactive colloidal chromic phosphate to control pleural effusion and ascites. J Am Med Assoc 1958, 166:597-599.
    • (1958) J Am Med Assoc , vol.166 , pp. 597-599
    • Jacobs, M.L.1
  • 66
    • 0007106163 scopus 로고
    • Summary of ten years of the use of radioactive colloids in intracavitary therapy
    • Card R.Y., Cole D.R., Henschke U.K. Summary of ten years of the use of radioactive colloids in intracavitary therapy. J Nucl Med 1960, 1:195-198.
    • (1960) J Nucl Med , vol.1 , pp. 195-198
    • Card, R.Y.1    Cole, D.R.2    Henschke, U.K.3
  • 67
    • 0016712161 scopus 로고
    • Loculation as a contraindication intracavitary 32P-chromic phosphate therapy
    • Taylor A., Baily N.A., Halpern S.E., Ashburn W.L. Loculation as a contraindication intracavitary 32P-chromic phosphate therapy. J Nucl Med 1975, 16:318-319.
    • (1975) J Nucl Med , vol.16 , pp. 318-319
    • Taylor, A.1    Baily, N.A.2    Halpern, S.E.3    Ashburn, W.L.4
  • 68
    • 50849130946 scopus 로고    scopus 로고
    • The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus
    • September
    • Baratti D., Kusamura S., Deraco M. The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus. J Surg Oncol 2008, 98(September (4)):258-262.
    • (2008) J Surg Oncol , vol.98 , Issue.4 , pp. 258-262
    • Baratti, D.1    Kusamura, S.2    Deraco, M.3
  • 69
    • 84856081843 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/ct2/show/NCT00796861Zterm=ascites&rank=8.
  • 70
    • 84856121341 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/ct2/show/NCT00826150Zterm=ascites&rank=56.
  • 71
    • 84856104576 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/ct2/show/NCT00796861.
  • 72
    • 33646409016 scopus 로고    scopus 로고
    • A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis
    • Hahn S.M., Fraker D.L., Mick R., et al. A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res 2006, 12:2517-2525.
    • (2006) Clin Cancer Res , vol.12 , pp. 2517-2525
    • Hahn, S.M.1    Fraker, D.L.2    Mick, R.3
  • 73
    • 0000925409 scopus 로고    scopus 로고
    • Intraperitoneal photodynamic therapy shows efficacy in phase I trial
    • Sindelar W., Sullivan F., Abraham E., et al. Intraperitoneal photodynamic therapy shows efficacy in phase I trial. Proc Am Soc Clin Oncol 2005, 14:447.
    • (2005) Proc Am Soc Clin Oncol , vol.14 , pp. 447
    • Sindelar, W.1    Sullivan, F.2    Abraham, E.3
  • 74
    • 33749663630 scopus 로고    scopus 로고
    • The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR
    • October
    • Pfisterer J., du Bois A., Sehouli J., et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 2006, 17(October (10)):1568-1577.
    • (2006) Ann Oncol , vol.17 , Issue.10 , pp. 1568-1577
    • Pfisterer, J.1    du Bois, A.2    Sehouli, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.